Targeting a protein complex to treat leukemia
Targeting PRC1 in leukemia
This study is exploring new ways to treat acute leukemia by developing small molecules that target a specific protein involved in the growth of cancer cells, with the hope of making these cells easier to treat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10913518 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for acute leukemia by targeting a specific protein complex known as PRC1, which plays a crucial role in the growth and survival of leukemic stem cells. The approach involves creating small molecules that inhibit the activity of PRC1, potentially leading to the differentiation and elimination of these resistant cancer cells. By using advanced screening techniques and medicinal chemistry, the researchers aim to discover effective compounds that can induce changes in leukemic cells, making them more susceptible to treatment. This innovative strategy could provide a new avenue for combating acute leukemia, which is often difficult to treat with existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute leukemia, particularly those with treatment-resistant forms of the disease.
Not a fit: Patients with other types of cancer or those who do not have acute leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target and eliminate resistant leukemic stem cells, improving outcomes for patients with acute leukemia.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Cierpicki, Tomasz — University of Michigan at Ann Arbor
- Study coordinator: Cierpicki, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.